 |
市場調査レポート
商品コード
1084776
DNA修復薬の世界市場の規模・シェア・展望・機会の分析 (2022年～2028年)：薬剤 (ニラパリブ・オラパリブ・ルカパリブ・タラゾパリブ)・用途・流通チャネル・地域別DNA Repair Drugs Market, by Drug (Niraparib, Olaparib, Rucaparib, Talazoparib, and Others), by Application by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| DNA修復薬の世界市場の規模・シェア・展望・機会の分析 (2022年～2028年)：薬剤 (ニラパリブ・オラパリブ・ルカパリブ・タラゾパリブ)・用途・流通チャネル・地域別 |
|
出版日: 2022年05月21日
発行: Coherent Market Insights
ページ情報: 英文 206 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
癌の発生率の増加、参入事業者によるM&A、製品の発売の増加などの要因が世界のDNA修復薬市場の成長を促進しています。また、製品ポートフォリオを強化するための主要企業による無機的戦略も同市場の成長を促進することが期待されています。
当レポートでは、世界のDNA修復薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
目次
第1章 調査目的・前提条件
第2章 市場概要
第3章 市場力学・法規制・動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 影響分析
- パイプライン分析
- 規制シナリオ
- 価格分析
- PEST分析
- 疫学
第4章 世界のDNA修復薬市場：薬剤タイプ別
- ニラパリブ（ゼジュラ）
- オラパリブ（リンパルザ）
- ルカパリブ（ルブラカ）
- タラゾパリブ（タルゼンナ）
第5章 世界のDNA修復薬市場：用途別
- 卵巣癌
- 乳癌
第6章 世界のDNA修復薬市場：流通チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
第7章 世界のDNA修復薬市場：地域別
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第8章 競合情勢
- 企業プロファイル
- AstraZeneca Plc.
- Johnson &Johnson
- GlaxoSmithKline plc.
- Pfizer, Inc.
- Clovis Oncology Inc.
- AbbVie Inc.
- Bristol Myers Squibb
- Merck KGaA
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- Karyopharm Therapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
第9章 セクション
目次
Product Code: CMI2617
DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.
Market Dynamics
Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.
Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.
Key features of the study:
- This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global DNA repair drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market
Detailed Segmentation:
- Global DNA Repair Drugs Market, By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- Global DNA Repair Drugs Market, By Application:
- Ovarian Cancer
- Breast Cancer
- Global DNA Repair Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global DNA Repair Drugs Market, By Region:
- North America
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- Latin America
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- AstraZeneca Plc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Johnson & Johnson
- GlaxoSmithKline plc.
- Pfizer, Inc.
- Clovis Oncology Inc.
- AbbVie Inc.
- Bristol Myers Squibb
- Merck KGaA
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- Karyopharm Therapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
- AstraZeneca Plc.*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
- Epidemiology
4. Global DNA Repair Drugs Market, By Drug Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Niraparib (Zejula)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Olaparib (Lynparza)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Rucaparib (Rubraca)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Talazoparib (Talzenna)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
5. Global DNA Repair Drugs Market, By Application, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
6. Global DNA Repair Drugs Market , By Distribution Channel, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
7. Global DNA Repair Drugs Market , By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- AstraZeneca Plc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Clovis Oncology Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol Myers Squibb
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck KGaA
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Genentech, Inc.
- Company Overview
- Product Type Portfolio
- Key Highlights
- Market Strategies
- Artios Pharma
- Company Overview
- Product Type Portfolio
- Key Highlights
- Market Strategies
- Repare Therapeutics Inc.
- Company Overview
- Product Type Portfolio
- Key Highlights
- Market Strategies
- Sierra Oncology, Inc.
- Company Overview
- Product Type Portfolio
- Key Highlights
- Market Strategies
- Karyopharm Therapeutics Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ono Pharmaceutical Co., Ltd.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Jiangsu Hengrui Medicine Co., Ltd.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
